TICKERNERD
Menu
STIMSTIMHealthcare · Medical Devices

STIM Stock Forecast: Neuronetics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$3.03
+0.66% on the day

The 3 Wall Street analysts covering Neuronetics, Inc. hold a median 12-month price target of $6 — +98.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 64 of 100 as at 12 Sept 2026 — in the upper half.

Market cap
$230.9M
Ticker Nerd rank
64 / 100
Median analyst target
$6.00
Analysts covering
3
Revenue$41.6M+9.1% y/y
Operating income−$1.5M
Net income−$3.4M
Free cash flow−$1.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+11.4%
1M
−5.0%
YTD
+119.6%
1Y
−12.4%
From 52W high
−12.4%
From 52W low
+156.8%
$1.18
$3.46
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

STIM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Neuronetics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
64 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
98
Revisions
93
Accruals
89
Size
66
Quality
43
Momentum
43
Value
20
Issuance
13
Volatility
8

Growth (98): Sales and profits are climbing, and climbing faster than before.

Volatility (8): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

STIM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on STIM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00$6.00$7.00Oct 25Jan 26Apr 26Jul 26STIMHigh $7.00Median $6.00Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $5.00Median $6.00High $7.00

The green dot is the last close — the median target sits +98.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
11 Sept 2026B. Riley SecuritiesInitiatesBuy$5.00
9 Sept 2026BTIGReiteratesBuy$6.00
11 Aug 2026BTIGMaintainsBuy$5.00 → $6.00
11 Aug 2026BTIGMaintainsBuy—
20 July 2026BTIGInitiatesBuy—
20 July 2026BTIGInitiatesBuy$5.00
19 Mar 2026Canaccord GenuityMaintainsBuy$7.00 → $3.00
19 Mar 2026Canaccord GenuityMaintainsBuy—
6 Aug 2025Canaccord GenuityMaintainsBuy—
5 Mar 2025Canaccord GenuityMaintainsBuy—
5 Mar 2025Citizens Capital MarketsMaintainsMarket Outperform—
14 Aug 2024JMP SecuritiesMaintainsMarket Outperform—
13 Aug 2024Canaccord GenuityMaintainsBuy—
12 Aug 2024William BlairDowngradeMarket Perform—
14 May 2024William BlairUpgradeOutperform—
6 Mar 2024Piper SandlerReiteratesOverweight—
10 May 2023JMP SecuritiesReiteratesMarket Outperform—
8 Mar 2023Canaccord GenuityMaintainsBuy—
8 Mar 2023JMP SecuritiesReiteratesMarket Outperform—
14 Oct 2021JMP SecuritiesMaintainsMarket Outperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. STIM appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

STIM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Neuronetics, Inc. returned −12.4% against +17.5% for the S&P 500, dividends included.

STIM vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Oct 25Jan 26Apr 26Jul 26STIMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

STIM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Neuronetics, Inc. (STIM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−5.1×

Cheaper than 90% of US stocks

Price / sales
1.5×

Cheaper than 60% of US stocks

Price / book
12.9×

Cheaper than 7% of US stocks

EV / EBITDA
−15.7×

Cheaper than 88% of US stocks

Growth & margins
Revenue growth (YoY)
9.1%

Higher than 49% of US stocks

Earnings growth (YoY)
9.1%

Higher than 47% of US stocks

Gross margin
51.1%

Higher than 63% of US stocks

Operating margin
−3.6%

Higher than 29% of US stocks

Net margin
−19.6%

Higher than 16% of US stocks

Returns & dividend
Return on equity
−116.1%

Higher than 12% of US stocks

Return on assets
−10.5%

Higher than 26% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Neuronetics, Inc. (STIM) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Neuronetics, Inc. has a market value of $230.9M and an enterprise value of $302.0M.

  • Revenue in the twelve months to 30 June 2026: $155.1M. The latest quarter grew 9.1% year on year.

  • Net income over the same four quarters: −$30.8M, a −19.9% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.44.

  • Free cash flow in the twelve months to 30 June 2026: −$11.3M.

  • Shares outstanding: 76.2M.

  • Trailing P/E: −5.1×; forward P/E: −8.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Neuronetics, Inc. employs 658 people — $236K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

STIM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
STIMNeuronetics, Inc.$230.9M
64
ELMDElectromed, Inc.$227.3M
94
INFUInfuSystem Holdings, Inc.$242.0M
100
RXSTRxSight, Inc.$249.2M
51
LABStandard BioTools, Inc.$269.1M
35
TLSITriSalus Life Sciences, Inc.$279.0M
34
TMCITreace Medical Concepts, Inc.$287.4M
56

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Neuronetics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest STIM news & analysis

NeuroStar Advances Practice Innovation with First-Ever TMS Integration with an EHR/EMR System

GlobeNewsWire · 8 Sept 2026positive

Neuronetics announced the integration of its TrakStar practice management platform with AdvancedMD, a cloud-based EHR, practice management, and revenue cycle platform serving more than 65,000 practitioners across 13,000 independent practices. This marks the first-ever TMS integration with an EHR/EMR system.

Why it matters — The integration could streamline practice workflows for NeuroStar TMS users and potentially expand the technology's adoption across a large base of independent mental-health practices.

Neuronetics, Inc. (STIM) Q2 2026 Earnings Call Transcript

Seeking Alpha · 11 Aug 2026neutral

Neuronetics, Inc. published its Q2 2026 earnings call transcript on Seeking Alpha, covering the company's second-quarter financial results and management discussion.

Why it matters — A STIM watcher would care because the transcript provides the company's official quarterly update, including its financial performance and commentary.

Neuronetics Q2 Earnings Call Highlights

MarketBeat · 11 Aug 2026positive

Neuronetics reported second-quarter 2026 revenue growth, a sharply narrower net loss, and positive adjusted EBITDA, driven by expansion of its Greenbrook clinic business and new commercial purchasing options for its NeuroStar TMS systems.

Why it matters — The financial results show improved operational performance and growing adoption of the company's core TMS therapy platform.

Neuronetics (STIM) Reports Q2 Loss, Beats Revenue Estimates

Zacks Investment Research · 11 Aug 2026positive

Neuronetics (STIM) reported a second-quarter loss of $0.05 per share, which was narrower than the Zacks Consensus Estimate of a $0.11 loss and an improvement from a $0.15 per share loss in the prior-year quarter.

Why it matters — A smaller-than-expected quarterly loss indicates improved financial performance versus analyst expectations and the year-ago period, which STIM watchers would track closely.

Neuronetics and Jorey Chernett Announce Shared Vision

GlobeNewsWire · 3 Aug 2026neutral

Neuronetics and Jorey Chernett — its second-largest shareholder and Managing Member of Pointillist Family Office — announced they have created a constructive framework, called the "Understanding," for alignment between the Company's Board, management, and Mr. Chernett.

Why it matters — Because Mr. Chernett is the Company's second-largest shareholder, this announced framework for board-management-shareholder alignment is directly relevant to STIM watchers following governance and shareholder relations.

FAQ

Frequently asked questions about STIM stock

What is the STIM stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Neuronetics, Inc. have a median 12-month price target of $6, with estimates ranging from $5 to $7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is STIM stock a buy right now?

Of the 3 analysts covering Neuronetics, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Neuronetics, Inc. 64 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank STIM?

As at 12 Sept 2026, Neuronetics, Inc. ranks 64 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (98 of 100).

Will STIM stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +98.0% from the last close, and Ticker Nerd's factor model ranks Neuronetics, Inc. 64 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the STIM stock forecast for 2030?

No analyst covering Neuronetics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for STIM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $7 over the next 12 months.

How has STIM stock performed over the past year?

Neuronetics, Inc. returned -12.4% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Neuronetics, Inc. do?

Neuronetics Inc. is a commercial-stage medical technology company focused on non-invasive neurohealth treatments.

What is the latest news on STIM?

The most recent item we track (GlobeNewsWire, 8 Sept 2026): "NeuroStar Advances Practice Innovation with First-Ever TMS Integration with an EHR/EMR System". Neuronetics announced the integration of its TrakStar practice management platform with AdvancedMD, a cloud-based EHR, practice management, and revenue cycle platform serving more than 65,000 practitioners across 13,000 independent practices. This marks the first-ever TMS integration with an EHR/EMR system.

Company

About Neuronetics, Inc.

Neuronetics Inc. is a commercial-stage medical technology company focused on non-invasive neurohealth treatments. Its core offering is the NeuroStar Advanced Therapy System, an office-based transcranial magnetic stimulation platform used primarily for adult patients with major depressive disorder. The company also provides related treatment sessions and support services, serving psychiatric practices and mental health providers in the United States and international markets. Neuronetics operates at the intersection of medical devices and clinic services, combining device commercialization with patient care delivery. Its products are designed to expand access to non-drug therapeutic options for psychiatric and neurological conditions, making the company a significant participant in the neuromodulation market.

CEO Mr. Daniel L. Reuvers · 658 employees · United States · https://neurostar.com/neuronetics